Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Challenging Market Timing And 60/40 - The Missing Component

8h seekingalpha
At the same time, they discourage those who would even consider timing the market; the topic is taboo. (144-0)

EDIT / Editas Medicine, Inc. 8-K (Current Report)

2018-02-17 sec.gov
edit_Current_Folio_8K_Hopfield Election   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2018 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001‑37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

EDIT / Editas Medicine, Inc. POWER OF ATTORNEY

2018-02-17 sec.gov
LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS   Know all by these present, that the undersigned hereby makes, constitutes and appoints each of Charlene Stern-Dombal, Anthony Joyce and Rhonda Chicko, signing singly and each acting individually, as the undersigned’s true and lawful attorney-in-fact with full power and authority as hereinafter described to:   (1)           execute for and on behalf of the undersigned, in the undersigned’s capacity as a director, officer and/or stoc

EDIT / Editas Medicine, Inc. POWER OF ATTORNEY

2018-02-17 sec.gov
LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS   Know all by these present, that the undersigned hereby makes, constitutes and appoints each of Charlene Stern-Dombal, Anthony Joyce and Rhonda Chicko, signing singly and each acting individually, as the undersigned’s true and lawful attorney-in-fact with full power and authority as hereinafter described to:   (1)           execute for and on behalf of the undersigned, in the undersigned’s capacity as a director, officer and/or stoc

EDIT / Editas Medicine, Inc. / Flagship Ventures Fund IV, L.P. - SC 13G/A (Passive Investment)

2018-02-14 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*     Editas Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28106W103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1

EDIT / Editas Medicine, Inc. / Flagship Ventures Fund IV, L.P. - SC 13G/A (Passive Investment)

2018-02-14 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*     Editas Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28106W103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1

EDIT / Editas Medicine, Inc. / STATE STREET CORP - EDITAS MEDICINE, INC. (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING EDITAS MEDICINE, INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 28106W103 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHA

EDIT / Editas Medicine, Inc. / STATE STREET CORP - EDITAS MEDICINE, INC. (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING EDITAS MEDICINE, INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 28106W103 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHA

EDIT / Editas Medicine, Inc. / Third Rock Ventures III, L.P. - SC 13G/A (Passive Investment)

2018-02-13 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)*     EDITAS MEDICINE, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 28106W103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1

EDIT / Editas Medicine, Inc. / Third Rock Ventures III, L.P. - SC 13G/A (Passive Investment)

2018-02-13 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)*     EDITAS MEDICINE, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 28106W103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1

EDIT / Editas Medicine, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 2 EDITAS MEDICINE INC COMMON STOCK Cusip #28106W103 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #28106W103 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,696,629 Item 6: 0 Item 7: 4,622,720 Item 8: 0 Item 9: 4,622,720 Item 11: 10.

EDIT / Editas Medicine, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 2 EDITAS MEDICINE INC COMMON STOCK Cusip #28106W103 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #28106W103 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,696,629 Item 6: 0 Item 7: 4,622,720 Item 8: 0 Item 9: 4,622,720 Item 11: 10.

Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics?

2018-02-09 seekingalpha
Gilead is poised for the upcoming growth with various key catalysts such as NASH, HCV's expansion into China, and CAR-T. (78-0)

EDIT / Editas Medicine, Inc. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-08 sec.gov
editasmedicineinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Editas Medicine Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  28106W103     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) R


CUSIP: 28106W103